carnitine has been researched along with HIV Infections in 43 studies
HIV Infections: Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Our first objective was to determine a blood lactate threshold predictive of survival in human immunodeficiency virus patients experiencing lactic acidosis related to nucleoside analogs, and second, to test l-carnitine for the treatment of patients exceeding that threshold." | 9.10 | Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. ( Azoulay, E; Branche, F; Cariou, A; Claessens, YE; Dhainaut, JF; Goldgran-Toledano, D; Monchi, M; Rouges, P; Soufir, L, 2003) |
| " NRTIs can induce mitochondrial impairment that leads to a number of adverse events, including symptomatic lactic acidosis." | 8.82 | Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. ( Cariou, A; Chiche, JD; Claessens, YE; Mira, JP, 2003) |
| "To evaluate plasma acylcarnitine profiles and their relationships with progression of carotid artery atherosclerosis among individuals with and without HIV infection." | 7.91 | Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection. ( Anastos, K; Clish, CB; Haberlen, SA; Hanna, DB; Hodis, HN; Hua, S; Kaplan, RC; Kizer, JR; Landay, AL; Lazar, JM; Post, WS; Qi, Q; Scott, JM; Shah, SJ; Yu, B, 2019) |
| "There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms." | 7.79 | Frequency of depression and its correlation with serum carnitine level in HIV/AIDS patients. ( Dashti-Khavidaki, S; Hatamkhani, S; Khalili, H; Khazaeipour, Z; Rezaee, H, 2013) |
| "We intended to find out the effectiveness of lactic acidosis therapy for mitochondrial toxicity." | 7.73 | [Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors]. ( Deig, E; Garrabou, G; Miró, O; Pedrol, E; Ribell, M; Soler, A; Villà, Mdel C, 2005) |
| "Depression is a frequent comorbidity in HIV infection that has been associated with worse treatment outcomes and increased mortality." | 5.42 | Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression. ( Cassol, E; Gabuzda, D; Kirk, GD; Mehta, SH; Misra, V; Morgello, S, 2015) |
| "Our first objective was to determine a blood lactate threshold predictive of survival in human immunodeficiency virus patients experiencing lactic acidosis related to nucleoside analogs, and second, to test l-carnitine for the treatment of patients exceeding that threshold." | 5.10 | Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine. ( Azoulay, E; Branche, F; Cariou, A; Claessens, YE; Dhainaut, JF; Goldgran-Toledano, D; Monchi, M; Rouges, P; Soufir, L, 2003) |
| " NRTIs can induce mitochondrial impairment that leads to a number of adverse events, including symptomatic lactic acidosis." | 4.82 | Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors. ( Cariou, A; Chiche, JD; Claessens, YE; Mira, JP, 2003) |
| "To evaluate plasma acylcarnitine profiles and their relationships with progression of carotid artery atherosclerosis among individuals with and without HIV infection." | 3.91 | Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection. ( Anastos, K; Clish, CB; Haberlen, SA; Hanna, DB; Hodis, HN; Hua, S; Kaplan, RC; Kizer, JR; Landay, AL; Lazar, JM; Post, WS; Qi, Q; Scott, JM; Shah, SJ; Yu, B, 2019) |
| "There are some evidences regarding beneficial effects of carnitine in improvement of depression symptoms." | 3.79 | Frequency of depression and its correlation with serum carnitine level in HIV/AIDS patients. ( Dashti-Khavidaki, S; Hatamkhani, S; Khalili, H; Khazaeipour, Z; Rezaee, H, 2013) |
| "We intended to find out the effectiveness of lactic acidosis therapy for mitochondrial toxicity." | 3.73 | [Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors]. ( Deig, E; Garrabou, G; Miró, O; Pedrol, E; Ribell, M; Soler, A; Villà, Mdel C, 2005) |
| " Gastrointestinal complaints and reversible liver transaminase elevations were the most frequently noted adverse events." | 2.68 | Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients. ( Barditch-Crovo, P; Cundy, KC; Ebeling, D; Hendrix, CW; Jaffe, HS; Lietman, PS; Toole, J, 1997) |
| "Adefovir dipivoxil is a novel nucleotide analogue with several promising in vitro anti-human immunodeficiency virus (HIV) characteristics." | 2.68 | The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial. ( Cherrington, JM; Collier, A; Deeks, SG; Drew, WL; Hellmann, N; Jaffe, HS; Kahn, J; Lalezari, J; Lamy, PD; Li, W; Mulato, AS; Pavia, A; Rodrigue, D; Toole, J, 1997) |
| "Phenazopyridine (Pyridium) is a commonly used urinary tract analgesic." | 2.43 | Acute renal failure due to phenazopyridine (Pyridium) overdose: case report and review of the literature. ( Abitbol, C; Berho, ME; Chandar, J; Espinoza, V; Onder, AM; Zilleruelo, G, 2006) |
| "L-carnitine is a nonessential micronutrient that regulates fatty acid transport into the mitochondrial matrix for metabolism via beta-oxidation." | 2.42 | Acetyl-L-carnitine for the treatment of HIV lipoatrophy. ( Day, L; Gerschenson, M; Shikuma, C, 2004) |
| "Neurodevelopmental delay and encephalopathy are complications of both HIV and GA1." | 1.48 | Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1 despite vertical HIV infection and minor head trauma. ( Ackermann, C; Cotton, MF; Dobbels, EFM; Laughton, B; Springer, PE; Thomas, A, 2018) |
| "Carnitine plays an essential role in fatty acid metabolism, exerts substantial antioxidant action and regulates immune functions." | 1.43 | Low levels of short- and medium-chain acylcarnitines in HIV-infected patients. ( Aukrust, P; Berge, RK; Damås, JK; Flo, TH; Landrø, L; Svardal, A; Ueland, T; Waagsbø, B; Øktedalen, O, 2016) |
| "Fasting insulin sensitivity was measured using homeostatic model assessment 2 (HOMA2), and adipose tissue was measured using dual-energy x-ray absorptiometry (DEXA)." | 1.43 | Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy. ( Culver, J; Jenkins, CA; Koethe, JR; Petucci, C; Shepherd, BE; Sterling, TR, 2016) |
| "Depression is a frequent comorbidity in HIV infection that has been associated with worse treatment outcomes and increased mortality." | 1.42 | Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression. ( Cassol, E; Gabuzda, D; Kirk, GD; Mehta, SH; Misra, V; Morgello, S, 2015) |
| "Carnitine was analysed by an enzymatic-spectrometric procedure, and amino acids by ion exchange chromatography." | 1.32 | Low serum carnitine in HIV-infected children on antiretroviral treatment. ( Artuch, R; Fortuny, C; López-Vilches, MA; Muñoz-Almagro, C; Pineda, J; Sierra, C; Vilaseca, MA, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (23.26) | 18.2507 |
| 2000's | 18 (41.86) | 29.6817 |
| 2010's | 12 (27.91) | 24.3611 |
| 2020's | 3 (6.98) | 2.80 |
| Authors | Studies |
|---|---|
| Kirmse, B | 4 |
| Hobbs, C | 1 |
| Aaron, L | 1 |
| Montepiedra, G | 1 |
| Summar, M | 3 |
| Williams, PL | 2 |
| Smith, CJ | 1 |
| Van Dyke, R | 1 |
| Yu, C | 2 |
| Ryckman, KK | 1 |
| Borkowsky, W | 3 |
| Binici, I | 1 |
| Akbay, Hİ | 1 |
| Huyut, Z | 1 |
| Alp, HH | 1 |
| Karsen, H | 1 |
| Koyuncu, I | 1 |
| Gonel, A | 1 |
| Akmeşe, Ş | 1 |
| Çelik, H | 1 |
| Roger, PM | 1 |
| Perre, PV | 1 |
| Haissman, JM | 1 |
| Haugaard, AK | 1 |
| Ostrowski, SR | 1 |
| Berge, RK | 2 |
| Hov, JR | 1 |
| Trøseid, M | 1 |
| Nielsen, SD | 1 |
| Jao, J | 1 |
| Powis, KM | 1 |
| Epie, F | 1 |
| Nshom, E | 1 |
| Abrams, EJ | 1 |
| Sperling, RS | 1 |
| Leroith, D | 1 |
| Geffner, ME | 1 |
| Kurland, IJ | 1 |
| Côté, HCF | 1 |
| Thomas, A | 1 |
| Dobbels, EFM | 1 |
| Springer, PE | 1 |
| Ackermann, C | 1 |
| Cotton, MF | 1 |
| Laughton, B | 1 |
| Okeke, NL | 1 |
| Craig, DM | 1 |
| Muehlbauer, MJ | 1 |
| Ilkayeva, O | 1 |
| Clement, ME | 1 |
| Naggie, S | 1 |
| Shah, SH | 1 |
| Hua, S | 1 |
| Scott, JM | 1 |
| Hanna, DB | 1 |
| Haberlen, SA | 1 |
| Shah, SJ | 1 |
| Hodis, HN | 1 |
| Landay, AL | 1 |
| Lazar, JM | 1 |
| Kizer, JR | 1 |
| Yu, B | 1 |
| Post, WS | 1 |
| Anastos, K | 1 |
| Kaplan, RC | 1 |
| Clish, CB | 1 |
| Qi, Q | 1 |
| Sinha, A | 1 |
| Ma, Y | 1 |
| Scherzer, R | 1 |
| Rahalkar, S | 1 |
| Neilan, BD | 1 |
| Crane, H | 1 |
| Drozd, D | 1 |
| Martin, J | 1 |
| Deeks, SG | 2 |
| Hunt, P | 1 |
| Hsue, PY | 1 |
| Rezaee, H | 1 |
| Khalili, H | 1 |
| Hatamkhani, S | 1 |
| Dashti-Khavidaki, S | 1 |
| Khazaeipour, Z | 1 |
| Cassol, E | 1 |
| Misra, V | 1 |
| Morgello, S | 1 |
| Kirk, GD | 1 |
| Mehta, SH | 1 |
| Gabuzda, D | 1 |
| Yao, TJ | 1 |
| Hofherr, S | 1 |
| Kacanek, D | 1 |
| Hobbs, CV | 2 |
| Hazra, R | 1 |
| Van Dyke, RB | 1 |
| Waagsbø, B | 1 |
| Svardal, A | 1 |
| Ueland, T | 1 |
| Landrø, L | 1 |
| Øktedalen, O | 1 |
| Flo, TH | 1 |
| Aukrust, P | 1 |
| Damås, JK | 1 |
| Koethe, JR | 1 |
| Jenkins, CA | 1 |
| Petucci, C | 1 |
| Culver, J | 1 |
| Shepherd, BE | 1 |
| Sterling, TR | 1 |
| Peter, I | 1 |
| Laplante, B | 1 |
| Caggana, M | 1 |
| Kloke, K | 1 |
| Raymond, K | 1 |
| Moretti, S | 2 |
| Famularo, G | 4 |
| Marcellini, S | 2 |
| Boschini, A | 2 |
| Santini, G | 1 |
| Trinchieri, V | 2 |
| Lucci, L | 1 |
| Alesse, E | 2 |
| De Simone, C | 4 |
| Walker, UA | 1 |
| Claessens, YE | 3 |
| Cariou, A | 3 |
| Monchi, M | 1 |
| Soufir, L | 1 |
| Azoulay, E | 1 |
| Rouges, P | 1 |
| Goldgran-Toledano, D | 1 |
| Branche, F | 1 |
| Dhainaut, JF | 2 |
| Chiche, JD | 2 |
| Mira, JP | 1 |
| Vilaseca, MA | 1 |
| Artuch, R | 1 |
| Sierra, C | 1 |
| Pineda, J | 1 |
| López-Vilches, MA | 1 |
| Muñoz-Almagro, C | 1 |
| Fortuny, C | 1 |
| Mosca, L | 1 |
| Day, L | 1 |
| Shikuma, C | 1 |
| Gerschenson, M | 1 |
| Pedrol, E | 1 |
| Ribell, M | 1 |
| Deig, E | 1 |
| Villà, Mdel C | 1 |
| Miró, O | 1 |
| Garrabou, G | 1 |
| Soler, A | 1 |
| Onder, AM | 1 |
| Espinoza, V | 1 |
| Berho, ME | 1 |
| Chandar, J | 1 |
| Zilleruelo, G | 1 |
| Abitbol, C | 1 |
| Mintz, M | 1 |
| Barditch-Crovo, P | 1 |
| Toole, J | 2 |
| Hendrix, CW | 1 |
| Cundy, KC | 1 |
| Ebeling, D | 1 |
| Jaffe, HS | 2 |
| Lietman, PS | 1 |
| Collier, A | 1 |
| Lalezari, J | 1 |
| Pavia, A | 1 |
| Rodrigue, D | 1 |
| Drew, WL | 1 |
| Mulato, AS | 1 |
| Lamy, PD | 1 |
| Li, W | 1 |
| Cherrington, JM | 1 |
| Hellmann, N | 1 |
| Kahn, J | 1 |
| Di Marzio, L | 1 |
| Zazzeroni, F | 1 |
| Ruggeri, B | 1 |
| Steinberg, SM | 1 |
| Cifone, MG | 1 |
| Cifone, G | 1 |
| Dauriat, G | 1 |
| Patrick, L | 1 |
| Highleyman, L | 1 |
| Maurice, J | 1 |
| Bellman, P | 1 |
| Loignon, M | 1 |
| Toma, E | 1 |
| Carr, A | 1 |
| Hudson, J | 1 |
| Chuah, J | 1 |
| Mallal, S | 1 |
| Law, M | 1 |
| Hoy, J | 1 |
| Doong, N | 1 |
| French, M | 1 |
| Smith, D | 1 |
| Cooper, DA | 1 |
| Simpson, DM | 1 |
| Katzenstein, D | 1 |
| Haidich, B | 1 |
| Millington, D | 1 |
| Yiannoutsos, C | 1 |
| Schifitto, G | 1 |
| McArthur, J | 1 |
| Bouvier, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Surveillance Monitoring for ART Toxicities Study in HIV Uninfected Children Born to HIV Infected Women[NCT01310023] | 3,400 participants (Anticipated) | Observational | 2007-03-31 | Recruiting | |||
| An Observational Cohort Study of Adipose Tissue and Immune Activation in Treated HIV Infection[NCT04439448] | 100 participants (Actual) | Observational | 2013-04-12 | Completed | |||
| Use of Acetyl L-Carnitine in Patients With Covid-19 Pneumonia[NCT04623619] | 100 participants (Anticipated) | Interventional | 2020-12-15 | Not yet recruiting | |||
| An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy[NCT00050271] | 27 participants (Actual) | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
7 reviews available for carnitine and HIV Infections
| Article | Year |
|---|---|
[Inherited and acquired disorders of mitochondrial DNA].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-HIV Agents; Cardiomyopathies; Carnitine; Child; Dia | 2002 |
Bench-to-bedside review: severe lactic acidosis in HIV patients treated with nucleoside analogue reverse transcriptase inhibitors.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Carnitine; HIV Infections; Humans; Lactic Acid; Mitochondr | 2003 |
Carnitines and its congeners: a metabolic pathway to the regulation of immune response and inflammation.
Topics: Animals; Carnitine; HIV Infections; Humans; Immunity, Mucosal; Inflammation; Rats; Systemic Inflamma | 2004 |
Acetyl-L-carnitine for the treatment of HIV lipoatrophy.
Topics: Acetylcarnitine; Carnitine; Fatty Acids; HIV Infections; HIV-Associated Lipodystrophy Syndrome; Huma | 2004 |
Acute renal failure due to phenazopyridine (Pyridium) overdose: case report and review of the literature.
Topics: Acetylcysteine; Acute Kidney Injury; Adolescent; Carnitine; Female; HIV Infections; Humans; Infectio | 2006 |
Carnitine in human immunodeficiency virus type 1 infection/acquired immune deficiency syndrome.
Topics: Carnitine; HIV Infections; HIV-1; Humans; Vitamin B Deficiency | 1995 |
Nutrients and HIV: part three - N-acetylcysteine, alpha-lipoic acid, L-glutamine, and L-carnitine.
Topics: Acetylcysteine; Antioxidants; Apoptosis; Carnitine; Complementary Therapies; Glutamine; HIV Infectio | 2000 |
11 trials available for carnitine and HIV Infections
| Article | Year |
|---|---|
L-carnitine reduces lymphocyte apoptosis and oxidant stress in HIV-1-infected subjects treated with zidovudine and didanosine.
Topics: Anti-HIV Agents; Apoptosis; Carnitine; Didanosine; Drug Therapy, Combination; fas Receptor; Flow Cyt | 2002 |
Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine.
Topics: Acidosis, Lactic; Adult; Antiviral Agents; Carnitine; Female; HIV Infections; Humans; Lactic Acid; M | 2003 |
Anti-human immunodeficiency virus (HIV) activity, safety, and pharmacokinetics of adefovir dipivoxil (9-[2-(bis-pivaloyloxymethyl)-phosphonylmethoxyethyl]adenine) in HIV-infected patients.
Topics: Adenine; Adult; Anti-HIV Agents; Carnitine; Digestive System; Double-Blind Method; Female; HIV Core | 1997 |
The safety and efficacy of adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults: a randomized, double-blind, placebo-controlled trial.
Topics: Adenine; Administration, Oral; Adult; Anti-HIV Agents; Carnitine; CD4 Lymphocyte Count; Cytomegalovi | 1997 |
Effect of L-carnitine on human immunodeficiency virus-1 infection-associated apoptosis: a pilot study.
Topics: Adult; Apoptosis; Carnitine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Ceramides; Fas | 1998 |
New drug, new hope.
Topics: Adenine; Anti-HIV Agents; Carnitine; CD4 Lymphocyte Count; Clinical Trials as Topic; Dose-Response R | 1998 |
Carnitine may boost T cell counts.
Topics: Adjuvants, Immunologic; Apoptosis; Carnitine; CD4 Lymphocyte Count; CD8-Positive T-Lymphocytes; HIV | 1998 |
L-Carnitine for the treatment of highly active antiretroviral therapy-related hypertriglyceridemia in HIV-infected adults.
Topics: Adult; Antiretroviral Therapy, Highly Active; Blood Glucose; Carnitine; Cholesterol; Female; HIV Inf | 2001 |
HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study.
Topics: Adenine; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Body Composition; Carnitine; Dideox | 2001 |
Carnitine for high triglycerides.
Topics: Adult; Carnitine; Female; HIV Infections; Humans; Hypertriglyceridemia; Male | 2001 |
Plasma carnitine in HIV-associated neuropathy.
Topics: Anti-HIV Agents; Carnitine; Dideoxynucleosides; HIV Infections; Humans; Nerve Growth Factor; Periphe | 2001 |
25 other studies available for carnitine and HIV Infections
| Article | Year |
|---|---|
Acylcarnitines and Genetic Variation in Fat Oxidation Genes in HIV-infected, Antiretroviral-treated Children With and Without Myopathy.
Topics: Anti-HIV Agents; Anti-Retroviral Agents; Carnitine; Child; Genetic Variation; HIV Infections; Humans | 2022 |
Determination of Serum Differential Carnitine Ester Levels in HIV(+) Patients: A Cross-Sectional Study.
Topics: Carnitine; Chromatography, Liquid; Cross-Sectional Studies; Esters; HIV Infections; Humans; Tandem M | 2023 |
l-Carnitine for immunological nonresponders to efficient antiretroviral therapy.
Topics: Anti-HIV Agents; Carnitine; HIV Infections; Humans | 2023 |
Microbiota-dependent metabolite and cardiovascular disease marker trimethylamine-N-oxide (TMAO) is associated with monocyte activation but not platelet function in untreated HIV infection.
Topics: Adult; Betaine; Biomarkers; Blood Platelets; Cardiovascular Diseases; Carnitine; Choline; Cross-Sect | 2017 |
Lower mitochondrial DNA and altered mitochondrial fuel metabolism in HIV-exposed uninfected infants in Cameroon.
Topics: Amino Acids, Branched-Chain; Anti-Retroviral Agents; Cameroon; Carnitine; DNA, Mitochondrial; Energy | 2017 |
Favourable outcome in a child with symptomatic diagnosis of Glutaric aciduria type 1 despite vertical HIV infection and minor head trauma.
Topics: Amino Acid Metabolism, Inborn Errors; Atrophy; Brain; Brain Diseases; Brain Diseases, Metabolic; Car | 2018 |
Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case-control study.
Topics: Adult; Biomarkers; Cardiovascular Diseases; Carnitine; Female; Glutamine; HIV Infections; Humans; Ma | 2018 |
Plasma acylcarnitines and progression of carotid artery atherosclerosis in HIV infection.
Topics: Adult; Atherosclerosis; Carnitine; Carotid Arteries; Carotid Artery Diseases; Female; HIV Infections | 2019 |
Carnitine Is Associated With Atherosclerotic Risk and Myocardial Infarction in HIV -Infected Adults.
Topics: Adult; Antiretroviral Therapy, Highly Active; Atherosclerosis; Betaine; Carnitine; Carotid Artery Di | 2019 |
Frequency of depression and its correlation with serum carnitine level in HIV/AIDS patients.
Topics: Adult; Carnitine; Cross-Sectional Studies; Depression; Female; HIV Infections; Humans; Incidence; Ma | 2013 |
Altered Monoamine and Acylcarnitine Metabolites in HIV-Positive and HIV-Negative Subjects With Depression.
Topics: Adult; Biogenic Monoamines; Carnitine; Cohort Studies; Depression; Female; HIV Infections; Humans; M | 2015 |
Acylcarnitine Profiles in HIV-Exposed, Uninfected Neonates in the United States.
Topics: Adult; Anti-HIV Agents; Carnitine; Child Development; Child, Preschool; Cohort Studies; Female; HIV | 2016 |
Low levels of short- and medium-chain acylcarnitines in HIV-infected patients.
Topics: Adult; Antiretroviral Therapy, Highly Active; Carnitine; Case-Control Studies; Disease Progression; | 2016 |
Superior Glucose Tolerance and Metabolomic Profiles, Independent of Adiposity, in HIV-Infected Women Compared With Men on Antiretroviral Therapy.
Topics: Absorptiometry, Photon; Adipose Tissue; Adiposity; Adult; Amino Acids, Branched-Chain; Anti-Retrovir | 2016 |
Abnormal newborn screens and acylcarnitines in HIV-exposed and ARV-exposed infants.
Topics: Anti-Retroviral Agents; Carnitine; Case-Control Studies; HIV Infections; Humans; Infant, Newborn; In | 2013 |
Low serum carnitine in HIV-infected children on antiretroviral treatment.
Topics: Adolescent; Anti-Retroviral Agents; Carnitine; Child; Child, Preschool; Cross-Sectional Studies; Fem | 2003 |
[Treatment of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors].
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Carnitine; HIV Infections; Humans; Lactic Acid; Male; Midd | 2005 |
Carnitine stands on its own in HIV infection treatment.
Topics: Apoptosis; Carnitine; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; HIV Infections; Humans | 1999 |
L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues.
Topics: Acidosis, Lactic; Adult; Anti-HIV Agents; Carnitine; Didanosine; Drug Therapy, Combination; HIV Infe | 2000 |
NDA submitted for adefovir.
Topics: Adenine; Carnitine; Drug Approval; Drug Packaging; Drug Therapy, Combination; HIV Infections; Humans | 1999 |
Expanded access for adefovir.
Topics: Adenine; Anti-HIV Agents; Carnitine; Drugs, Investigational; HIV Infections; Humans | 1998 |
High triglyceride levels: their danger and what can be done.
Topics: Ascorbic Acid; Carnitine; Female; HIV Infections; Humans; Hypertriglyceridemia; Male; Triglycerides; | 1998 |
AIDS practice issues today: interview with Paul Bellman, M.D. Interview by John S. James.
Topics: Anti-HIV Agents; Carnitine; Drug Administration Schedule; Drug Costs; Drug Resistance, Microbial; Dr | 2000 |
Not so mighty mitochondria.
Topics: Anti-HIV Agents; Apoptosis; Ascorbic Acid; Carnitine; HIV Infections; Humans; Mitochondria, Muscle; | 2001 |
Nutrition. L-carnitine for the treatment of hypertriglyceridemia in HIV.
Topics: Antiretroviral Therapy, Highly Active; Carnitine; Dietary Supplements; HIV Infections; Humans; Hyper | 2002 |